No Data
Needham Maintains Geron(GERN.US) With Buy Rating, Maintains Target Price $6
Sector Update: Health Care Stocks Steady Premarket Friday
Express News | Needham Reiterates Buy on Geron, Maintains $6 Price Target
Buy Rating on Geron Driven by EU Approval Prospects and Strategic Commercialization of Rytelo
Geron's Rytelo Secures European Medicines Agency Committee's Approval Recommendation
Geron Says Committee For Medicinal Products For Human Use Of The European Medicines Agency Has Recommended Approval Of RYTELO (Imetelstat) For Treatment Of Adult Patients With Transfusion-dependent (TD) Anemia Due To Very Low, Low Or Intermediate Risk...
No Data
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}